| Recruiting | Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) NCT07240558 | University Health Network, Toronto | Phase 3 |
| Active Not Recruiting | Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart NCT07275060 | Canadian Immunization Research Network | Phase 4 |
| Active Not Recruiting | A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healt NCT07019883 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | 2017 A/H7N9 IIV Revaccination NCT03738241 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza NCT03682120 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | 2013/2017 H7N9 Prime-Boost Interval NCT03589807 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | H5N1 With or Without Topical Aldara in Healthy Adults NCT03472976 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 NCT03318315 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly NCT03312231 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Safety and Immunogenicity Study of IVACFLU-A/H5N1 NCT02612909 | Institute of Vaccines and Medical Biologicals, Vietnam | Phase 2 / Phase 3 |
| Completed | H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology NCT03014310 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analys NCT02921997 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults NCT02624219 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine NCT02839330 | Seqirus | Phase 3 |
| Completed | A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Follo NCT02251288 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | H7N9 Mix and Match With MF59 in Healthy Elderly Persons NCT02213354 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine NCT02229357 | Mahidol University | Phase 2 |
| Completed | A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 NCT01897701 | Novavax | Phase 1 |
| Completed | Safety and Pharmacokinetics Study of FBF001 NCT02295813 | Fab'entech | Phase 1 |
| Completed | Immunogenicity of ND1.1 by Delivery Directly to the Ileum NCT01698060 | Vaxart | Phase 1 |
| Completed | A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 In NCT01675284 | Medigen Biotechnology Corporation | Phase 1 |
| Completed | Safety Trial of Live Attenuated Influenza (H7N3) Vaccine NCT01511419 | PATH | Phase 1 |
| Completed | Safety Study of an Oral Vaccine to Prevent Avian Influenza NCT01335347 | Vaxart | Phase 1 |
| Completed | Studies of Avian Influenza Transmission to Humans in Egypt NCT01150552 | St. Jude Children's Research Hospital | — |
| Completed | Avian Influenza Studies In Lebanon NCT01107262 | St. Jude Children's Research Hospital | — |
| Completed | Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in NCT00895544 | Alachua Government Services, Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine NCT00561184 | Novartis Vaccines | Phase 2 |
| Completed | Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subje NCT00481065 | Novartis | Phase 2 |
| Completed | High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza NCT00298233 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |